Your browser doesn't support javascript.
Adalimumab effect on COVID-19
IRCT; 2020-06-18; TrialID: IRCT20171105037262N4
Clinical Trial Register | ICTRP | ID: ictrp-IRCT20171105037262N4
ABSTRACT

Condition

COVID-19.
COVID-19, virus identified;U07.1

Intervention

Intervention 1 Intervention group 50 patients with COVID-19 who receive routine antiviral treatment and chloroquine, have more than normal levels of TNF-a, and are at risk of critical disease statement (1-respiratory failure that needs mechanical ventilation, 2-shock, 3-any organ failure, 4-need to be admitted in ICU) will receive subcutaneous injection of anti-TNF-a (adalimumab), 40 mg, in periumbilical region of the abdomen. According to altered clinical and laboratory findings, mentioned dose can be repeated. Intervention 2 Control group 50 matched patients receiving equal antiviral treatment and chloroquine.

Primary 

outcome:

Disease severity. Timepoint At the beginning and end of the intervention. Method of measurement According to protocol and clinical symptoms.

Criteria

Inclusion criteria Having COVID-19
Respiratory distress with over 30 breaths per minute
O2 saturation less than 93% at rest
PaO2/Fio2 less than 300 mmHg
HRCT indicating COVID-19
positive PCR test result

Exclusion criteria
Collection: Clinical trial registers Database: ICTRP Year: 2020 Document Type: Clinical Trial Register

Similar

MEDLINE

...
LILACS

LIS

Collection: Clinical trial registers Database: ICTRP Year: 2020 Document Type: Clinical Trial Register